{"prompt": "['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 75 of 81', 'The signed informed consent statement is to remain in the investigator site file or, if locally', \"required, in the patient's note/file of the medical institution.\", 'In the event that informed consent is obtained on the date that baseline study procedures are', \"performed, the study record or patient's clinical record must clearly show that informed\", 'consent was obtained prior to these procedures.', 'If the patient is not capable of providing a signature, a verbal statement of consent can also be', 'given in the presence of an impartial witness (independent of the sponsor and the', 'investigator). This is to be documented by a signature from the informing physician as well as', 'by a signature from the witness.', 'The informed consent form and any other written information provided to patients / legal', 'representatives will be revised whenever important new information becomes available that', \"may be relevant to the patient's consent, or there is an amendment to the protocol that\", 'necessitates a change to the content of the patient information and / or the written informed', 'consent form. The investigator will inform the patient / legal representative of changes in a', 'timely manner and will ask the patient to confirm his/her participation in the study by signing', 'the revised informed consent form. Any revised written informed consent form and written', \"information must receive the IEC/IRB's approval / favorable opinion in advance of use.\", '13.5', 'Publication policy and use of data', 'The sponsor has made the information regarding the study protocol publicly available on the', 'internet at www.clinicaltrials.gov', 'Regarding public disclosure of study results, the sponsor will fulfill its obligations according', 'to all applicable laws and regulations. The sponsor is interested in the publication of the', 'results of every study it performs.', 'The sponsor recognizes the right of the investigator to publish the results upon completion of', 'the study. However, the investigator, whilst free to utilize study data derived from his/her', 'center for scientific purposes, must obtain written consent of the sponsor on the intended', 'publication manuscript before its submission. To this end, the investigator must send a draft', 'of the publication manuscript to the sponsor within a time period specified in the contract.', 'The sponsor will review the manuscript promptly and will discuss its content with the', 'investigator to reach a mutually agreeable final manuscript.', '13.6', 'Compensation for health damage of patients / insurance', 'The sponsor maintains clinical trial insurance coverage for this study in accordance with the', 'laws and regulations of the country in which the study is performed.', '13.7', 'Confidentiality', 'All records identifying the patient will be kept confidential and, to the extent permitted by the', 'applicable laws and/or regulations, will not be made publicly available.', 'Patient names will not be supplied to the sponsor. Only the patient number will be recorded in', 'the CRF, and if the patient name appears on any other document (e.g. pathologist report), it', 'must be obliterated before a copy of the document is supplied to the sponsor. Study findings', 'stored on a computer will be stored in accordance with local data protection laws. As part of', 'the informed consent process, the patients will be informed in writing that representatives of']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 76 of 81', 'the sponsor, IEC/IRB, or regulatory authorities may inspect their medical records to verify the', 'information collected, and that all personal information made available for inspection will be', 'handled in strictest confidence and in accordance with local data protection laws.', \"If the results of the study are published, the patient's identity will remain confidential.\", 'The investigator will maintain a list to enable patients to be identified.', '14.', 'Reference list', '1.', 'Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al.', 'Trends in patients hospitalized with heart failure and preserved left ventricular ejection', 'fraction: prevalence, therapies, and outcomes. Circulation. 2012 Jul 3; ;126(1):65-75.', '2.', 'Butler J, Hamo CE, Udelson JE, Pitt B, Yancy C, Shah SJ, et al. Exploring New', 'Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circ', 'Heart Fail. 2016 Nov;9(11).', '3.', 'Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat now by', 'treating comorbidities. Jama. 2008 Jul 23;300(4):431-3', '4.', 'Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Colvin MM, et al. 2017', 'ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the', 'Management of Heart Failure: A Report of the American College of Cardiology', '/American Heart Association Task Force on Clinical Practice Guidelines and the Heart', 'Failure Society of America. J Am Coll Cardiol. 2017 Aug 08;70(6):776-803.', '5.', 'Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC', 'Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task', 'Force for the diagnosis and treatment of acute and chronic heart failure of the', 'European Society of Cardiology ESC)Developed with the special contribution of the', 'Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-', '200.', '6.', 'Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes', 'within the heart failure spectrum. Circulation. 2011 May 10;123(18):2006-13;', 'discussion 14.', '7.', 'Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and', 'therapeutics. Pharmacology & therapeutics. 2009 Jun; 22(3):216-38.', '8.', 'van Heerebeek L, Hamdani N, Falcao-Pires I, Leite-Moreira AF, Begieneman MP,', 'Bronzwaer JG, et al. Low myocardial protein kinase G activity in heart failure with', 'preserved ejection fraction. Circulation. 2012 Aug 14;126(7):830-9.', '9.', 'Buys ES, Sips P, Vermeersch P, Raher MJ, Rogge E, Ichinose F, et al. Gender-', 'specific hypertension and responsiveness to nitric oxide in sGCalphal knockout mice.', 'Cardiovascular research. 2008 Jul 01;79(1): 179-86.', '10.', 'Lam CS, Brutsaert DL. Endothelial dysfunction: a pathophysiologic factor in heart', 'failure with preserved ejection fraction. J Am Coll Cardiol. 2012 Oct 30;60(18):1787-', '9.', '11.', 'Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ', 'Res. 2005 Sep 30;97(7):618-28', '12.', 'Oelze M, Knorr M, Kroller-Schon S, Kossmann S, Gottschlich A, Rummler R, et al.', 'Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction,', 'oxidative stress, and a marked increase in vascular endothelin-1 expression. Eur Heart', 'J. 2013 Nov;34(41):3206-16.']\n\n###\n\n", "completion": "END"}